Combination therapy using CD19- and CD22-CAR-T in adult and pediatric B-ALL patients significantly enhanced the median OS (88.5% for 12 months) and progression-free survival (survival rate 67.5% for 18 months) rate and duration [226]. This evidence concerns the gene CD19 and precursor B-cell acute lymphoblastic leukemia.